Related Experiment Videos
Cancer complicating systemic lupus erythematosus--a dichotomy emerging from a nested case-control study
1Centre for Rheumatology, Department of Medicine, University College London Hospitals, London, UK. dzifakay@hotmail.com
Lupus
|July 17, 2013
Summary
Systemic lupus erythematosus (SLE) patients show a small, insignificant increase in overall cancer risk, with higher rates of cervical and prostate cancers but lower rates of breast cancer. Survival is significantly reduced post-cancer diagnosis.
Area of Science:
- Rheumatology
- Oncology
- Epidemiology
Background:
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with complex associations.
- Understanding cancer risk in SLE patients is crucial for long-term management and prognosis.
Purpose of the Study:
- To investigate cancer incidence and types in SLE patients.
- To identify clinical and serological factors associated with cancer risk in SLE.
- To determine the prognosis of cancer in SLE patients.
Main Methods:
- Retrospective review of 595 SLE patients followed for up to 32 years.
- Nested case-control design comparing cancer patients with matched controls.
- Multivariate analysis to identify associated risk factors.
Main Results:
- 33 SLE patients developed cancer; overall cancer risk was insignificantly increased (SIR 1.05).
- Increased risk observed for cervical, prostate, anal, and pancreatic cancers; decreased risk for breast cancer.
- Haematological/musculoskeletal issues and specific antibodies (anticardiolipin, antithyroid globulin) linked to increased risk.
- No association found between cancer risk and drug, dose, or duration.
- Significantly reduced survival post-cancer diagnosis (84.2% fatality rate).
Conclusions:
- SLE patients face a small, statistically insignificant increase in cancer risk, with varying risks for specific cancer types.
- Clinical and serological factors play a role in malignancy risk in SLE.
- Cancer diagnosis in SLE patients is associated with a poor prognosis and reduced survival.
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...